Skip to content
Bored Studies
RecruitingPhase 3

IS-001 Injection in Patients Undergoing Robotic-Assisted Colorectal Surgery

Intuitive Surgical · NCT07346066

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 16–75 · All sexes
Healthy volunteers
Not accepted (a condition is required)
Study type
Interventional · Phase 3
Target enrollment
146
US sites recruiting
6
Study start
May 14, 2026
Record last updated
August 5, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

This study evaluates the safety and efficacy of intravenous injection of IS-001 to aid in intraoperative ureter structure delineation

Being studied: filricianine

Conditions: Ureter Injury

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Male and female participants between the ages of 16 and 75, inclusive
  • Participant is scheduled to undergo robotic-assisted colectomy using the da Vinci X/Xi Surgical System with SFF Fluorescence Imaging Exclusion Criteria
  • Participant is pregnant or nursing 2. Participant has known current acute or chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infection 3. Participant has any of the following screening laboratory values: eGFR \< 30 mL/min/1.73 m2
  • Aspartate aminotransferase (AST) ≥ 2.5 × ULN
  • Alanine aminotransferase (ALT) ≥ 2.5 × ULN
  • Total Bilirubin > 2mg/dL 4. Participant has any concomitant non-colorectal cancer 5. Participant has any circumstances that, in the judgment of the Investigator, might make them not a suitable candidate for the study 6. Participants have already been enrolled in another investigational drug or device study within the past 6 months 7. Participants with known or suspected hypersensitivity to indocyanine green (ICG) or any components of the formulation used 8. Participant is expected to receive or has received other methods for ureter identification during the surgery (e.g., ureteral stent placement, illuminated catheters, retrograde ICG injections) before the administration of IS-001 9. The duration of the surgery is expected to be less than 90 minutes as determined during preoperative planning.

Recruiting US locations

  • Hoag Memorial Hospital Presbyterian

    Newport Beach, CA 92663

    Site contact: Vianh Truong · 949-764-5597 · vianh.truong@hoag.org

  • Yale New Haven Hospital

    New Haven, CT 06510

    Site contact: Kyra Jersey · 203-688-4242 · kyra.jersey@yale.edu

  • Orlando Health

    Orlando, FL 32806

    Site contact: Patty Camacho · 321-842-4130 · Patty.Camacho@orlandohealth.com

  • Mountain View Hospital

    Las Vegas, NV 89128

    Site contact: Coral Rodriguez · 702-255-5000 · coral.rodriguez@hchealthcare.com

  • St David's North Austin Medical Center

    Austin, TX 78758

    Site contact: Krishna Saini · 5125448070 · Krishna.Saini@stdavids.com

  • HCA Houston Healthcare Medical Center

    Houston, TX 77004

    Site contact: Jimena Alcocer-Barrios · 713-527-5000 · jalcocerbarrios@houstoncolon.com

Study contacts (from the official record)

  • Clinical Project Manager · 4085232100 · info.is-001@intusurg.com
IS-001 Injection in Patients Undergoing Robotic-Assisted… (NCT07346066) | Bored Studies